Sentences with phrase «data on drug»

Although the study lacks evidence on whether marijuana was involved in any of the April 20th fatalities (as there was no police data on drug testing to confirm that marijuana was involved), researchers believe that the drug was responsible for some of the crashes.

There are other items to collect as well, such as letters from World War II that fill in the back story of the island's role during that time and memory cards that contain data on its drug connection.

«Kavanagh recalls being given records of safety data on a drug — and then his bosses told him which sections not to read.

Most American trials of AZT (zidovudine) were stopped early for ethical reasons, so data on the drug's long - term effects have been scarce until now.

The new analysis includes data on drug resistance in 39 countries, and profiles of antibiotic use in 69 countries, and is the first time such data has been combined.

Another promising drug for ALS is being developed by French drugmaker AB Science SA (ABS.PA), which in March reported positive late - stage data on its drug, masitinib.

Researchers at Washington University School of Medicine in St. Louis examined data on drug use collected from young people, ages 12 to 17, over a 12 - year span.

By applying the algorithm to 2010 data on drug crime reports for Oakland, the researchers generated a predicted rate of drug crime on a map of the city for every day of 2011.

Although the FDA collects safety data on drugs, experts estimate that only a fraction of the potentially related harms and deaths — about 10 to 50 percent — end up in FDA databases, in part because reporting is voluntary.

Lööf, a physician at Central Hospital in Västerås who specializes in internal medicine and gastroenterology, said he and many of his colleagues feel the database is useful but that it needs more hard data on drugs, especially older ones that don't fall under EU legislation.

Not exact matches

Hospitals and pharmacies shelled out $ 424.8 billion on drugs, up 12.2 % from 2014's record mark, according to new data from the IMS Institute for Healthcare Informatics.

With city data indicating that African - Americans have been charged with marijuana crimes twice as frequently as white residents, the Oakland City Council voted unanimously in March to allocate 50 percent of medical marijuana and cannabis sales permits to people affected by the war on drugs.

On February 26, 2018, post-market, Fresenius announced that it is conducting an independent investigation, using external experts, into alleged breaches of U.S. Food and Drug Administration data integrity requirements relating to product development at Akorn.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

And Marathon barely did any actual clinical legwork to get the drug cleared for Duchenne — it relied on 1990 - era clinical trial data before tacking on just enough study material to win an approval that doesn't even address the root cause of the disease.

Rõivas, the former Prime Minister, says Estonia is working on developing «precision medicine» that would tap into the genome data of its 1.3 million citizens in order to better diagnose illnesses, treat people, and design personalized drugs.

While it's been facing some sales problems on the former front, the biotech is now attempting to strengthen its position in the latter with solid new data for an HIV treatment cocktail combining bictegravir with emtricitabine / tenofovir alafenamide, two of its main drugs for the virus.

The Finnish drug maker on Sunday presented results from phase I trial of a prostate cancer treatment, saying according the data it «has been well tolerated, with no significant treatment - related adverse events.»

But research violations — including inappropriate drug testing on children and falsified data — forced the school to repay a National Institute of Mental Health grant for a whopping $ 3.1 million.

«The data makes it clear that ending the War on Drugs will not alone end mass incarceration, but that the federal government and some states have effectively reduced their incarcerated populations by turning to drug policy reform,» the report says.

Analysts have said that the company could make for a good acquisition, but more data on its cancer immunotherapy drugs may need to come in first.

In January, Mallinckrodt raised its price to $ 36,382 a vial, according to the data provider Truven, but that wasn't far off what it cost back in 2015 when Medicare Part D, a prescription drug program, spent over $ 500 million on the drug, making it one of the top 20 expenses for the program, government data shows.

Specifically, the process allows early approval of a drug to treat a serious or life - threatening disease based on clinical data.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The latest factory orders data show that pharmaceutical shipments are booming, consistent with robust consumer outlays on drugs.

New drug launches, Big Pharma and specialty drug maker news, deal making, manufacturing, marketing, clinical data on approved drugs

The company focuses on cancer drug research and has a platform for so - called «real - world» data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.

The most anticipated event for Biogen Idec's drug pipeline, Friday's release of data on its experimental Alzheimer's medicine, started 12 years ago with the rekindling of an old friendship.

Additional clinical trial data later this year on Tesaro's key drug, Niraparib, which targets advanced solid tumors in ovarian and breast cancers, could help narrow the valuation gap, the people said.

The pressure on Mr. Cohen, 56, escalated in November, when prosecutors charged Mathew Martoma, a former SAC portfolio manager, with trading in the drug stocks Elan and Wyeth based on confidential drug trial data that a doctor had leaked to him.

Last year, the FDA issued final guidance on the use of real - world data for the development of devices, and FDA Commissioner Scott Gottlieb has pledged to issue guidance on real - world data for both pre-and post-marketing drug studies.

It also asks for data on studies comparing the proposed drug to the approved brand - name drug, called the «reference drug,» and asks for data from studies conducted on the generic drug.

Court documents made public late on Tuesday show that Fresenius (NYSE: FMS) dropped its acquisition of Akorn after uncovering evidence that the generic drug developer submitted fraudulent data to the U.S. Food and Drug Administration for at least six different drugs dating back to 2drug developer submitted fraudulent data to the U.S. Food and Drug Administration for at least six different drugs dating back to 2Drug Administration for at least six different drugs dating back to 2012.

The latter is particularly important as regulatory approval for new drugs hinges on accurate data, and public trust in the pharma industry has ebbed and flowed over the years as stories of fabricated results make headlines.

Detectives needed access to data stored on the handset potentially linked to a drug investigation, an official said.

Among its top holdings, Intra-Cellular Therapies (ITCI) was up more than 11 %, continuing a run that has helped the stock double in price since the end of August following positive data on late - stage experimental schizophrenia drug candidate ITI - 007.

Looking at sixty - seven recent drug discovery projects based on preclinical cancer biology research, they found that in more than 75 percent of cases the published data did not match up with their in - house attempts to replicate.

As Business Insider notes, «Based on seven major illegal drug data surveillance systems, the researchers found that heroin, cocaine and marijuana became significantly cheaper and more potent from 1990 to 2007 (the last year for which data is publicly available).»

Even if you are not for the large - scale decriminalization of some drugs, much of the data suggests that there are major flaws in the War on Drugs» strategy of sentencing of enforcedrugs, much of the data suggests that there are major flaws in the War on Drugs» strategy of sentencing of enforceDrugs» strategy of sentencing of enforcement.

And based on the U.S. Food and Drug Administration's data on rice, just one serving of rice cereal or many other rice products could put a baby close to that limit.

This new and expanded reference has data on more than 1,300 drugs, syndromes, vaccines, herbals, and many other substances.

They also took into account mother's age, the baby's birth weight, the position the baby was last left in and other important factors, but they only had the data on the mother's alcohol and illegal drug usage for two of the five studies — a pretty significant limitation to the overall analysis.

For the purposes of this economic evaluation, the forms were initially used in a related study funded by the National Institute of Health Research (NIHR) research for patient benefit programme «assessing the impact of a new birth centre on choice and outcome of maternity care in an inner city area,» which will be reported in full elsewhere, comparing the costs of care in a free standing midwifery unit with care in an obstetric unit in the same trust.16 The data collected included details of staffing levels, treatments, surgeries, diagnostic imaging tests, scans, drugs, and other resource inputs associated with each stage of the pathway through intrapartum and after birth care.

We have posted the raw data on our website in the same manner that the Food and Drug Administration (FDA) does as part of their FDA Total Diet study.

For all women included in the study, we collected data on their age, height, weight before pregnancy, body mass index, income quintile, drug and alcohol use (v. no use) during pregnancy, smoking status, status of parenthood (single v. other), parity, gestational age at first prenatal visit, number of antenatal visits and history of ultrasonography before 20 weeks» gestation.

Data on the long - term safety of psychoactive drugs are limited, yet the report does not recommend advising these women to stop breastfeeding.

Access to the New York State Medicaid Data Warehouse gives Erie County real - time information on Medicaid activity, such as the most commonly prescribed drugs for Medicaid patients.

The study crunched the numbers in the United Nations World Drug Report 2017, along with the most recent population data available, and worked on the assumption that the average joint weighs 0.66 grams.

First, he said it was based on one - sided data that mail - order companies provided to the FTC and second, it reflected a market dominated by brand name drugs.

«But we have to be honest and say that, based on all the evidence, including data presented by the drug companies themselves, our experts have concluded that these drugs do not make enough of a difference for us to recommend their use for treating all stages of Alzheimer's disease.